| Products | Technical Support | Search | Sitemap | Contact | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| INSTITUTE OF ISOTOPES CO., LTD. | Free triiodothyronine (FT3) RIA kit (RK-33CT) - coated tube | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| COMPANY About Us Contact BUSINESS UNITS Radiopharmaceutical Immunoassay Molecular Biology Synthesis Radiation Technique PRODUCTS Complete List New Products Technical Support QUOTATION REQUEST SEARCH || Sitemap *** Magyar *** |
DescriptionThe FT3 [125I] RIA system provides a quantitative in vitro determination of free triiodothyronine (FT3) in human serum in the range 0-40 pmol/l (0-26 pg/ml). IntroductionAmong the thyroid hormones produced in the thyroid gland triiodothyronine (3,5,3'-triiodo-L-thyronine, T3) is regarded as the most biologically active molecule, produced up to 80% by the deiodination of tetraiodothyronine (T4) in pheripheral tissues. T3 is found in the bloodstream in a major (99.7%) protein-bound, and a minor (0.3%) unbound, fraction. Variations in total thyroid hormone in blood may result from either changes of binding proteins concentrations, or thyroid hormone production. Thyroid disorders are existing only if a net change of free unbound fractions occur persistently, therefore the true measure of thyroid status will be the concentration of free hormones. Hyperthyroidism is generally associated with an increase of the FT3 concentration, and in some cases the increased FT3 concentration is the only indicator of T3 thyrotoxicosis. Determination of the free T3 concentration allows also the follow-up of patients under liothyronine therapy. Principle of methodThis assay is based on the competition between FT3 and conjugate (T3 analog bound to biotinylated carrier protein) for a limited number of binding sites on 125I-labelled monoclonal anti-triiodothyronine antibodies (tracer). Allowing to react a fixed amount of conjugate and antibody with different amounts of ligand the radioactivity measured on the solid phase will be inversely proportional to the concentration of ligand. During a 2-hour incubation period with continuous agitation immuno-complex is immobilized on the reactive surface of test tubes. Decanting the supernatant from all tubes the radioactivity in tubes can be measured in a gamma counter. By plotting binding values against a series of calibrators containing known amount of FT3, a calibration curve is constructed, from which the unknown concentration of FT3 in patient samples can be determined. Contents of the kit
Materials, tools and equipment requiredTest
tube rack Recommended tools and equipment Repeating pipettes Preparation of reagents, storageTracer, standard and conjugate solutions are ready to use. Add 500 µl distilled water to the lyophilized control serum. Mix gently with shaking or vortexing (foaming should be avoided). Ensure that complete dissolution is achieved and allow the solution to equilibrate at room temperature for at least 20 minutes. Specimen collection and storageSerum samples can be prepared according to common procedures used routinely in clinical laboratory practice. Samples can be stored at 2-8 °C if the assay is carried out within 24 hours, otherwise aliquots should be prepared and stored deep frozen (-20 °C). Frozen samples should be thawed and thoroughly mixed before assaying. Repeated freezing and thawing should be avoided. Do not use lipemic, hemolyzed or turbid specimens. Assay procedure(For a quick guide, refer to Table 1.)
Table 1. Assay Protocol, Pipetting Guide (all volumes in microliters)
Calculation of resultsThe
calculation is illustrated using representative data. The assay data collected should be
similar to those shown in Table 2.
Calculate the normalized percent binding for each standard, control and sample respectively by using the following equation:
For simplicity, these values are uncorrected for non-specific binding (NSB). This is enabled by low NSB being less than 1.5% of total count. Using semi-logarithmic graph paper plot B / B0 (%) for each standard versus the corresponding concentration of FT3. Figure 1 shows a typical standard curve. Determine the FT3 concentration of the unknown samples by interpolation from the standard curve. Do not extrapolate values beyond the standard curve range. Out of fitting programs applied for computerized data processing logit-log, or spline fittings can be used. Table 2. Typical assay data (Do not use to calculate sample values)
Characterization of the assayTypical assay parameters
Conversion of SI units can be performed according to the following formula: 1 pmol/l = 0.0651 ng/dl Specificity Four analytes were added in different concentrations to T3 free standard (S1=B0) and the concentration of FT3 was measured.
DL –
detection limit Better
than 0.58 pmol/l, corresponding to the 0–2*SD value. The within-assay precision was determined with 10 replicates within a single run, the between-assay precision was estimated in 13 independent runs carried out in duplicates (using different shakers, range of temperature during incubation: 20-30 °C), both with 5 samples. CV values are summarized below.
Expected Values It is recommended that each laboratory establish its own reference intervals. The expected values presented here are based on testing of apparently healthy blood donors. Samples were measured in duplicates. From statistical analysis the following results were obtained.
BL = Borderline for upper and lower 2.5% from distribution. As a guide (mean ± 2*SD), 2.09 – 5.21 pmol/l reference range was obtained from normal patients based on statistical considerations only. Taking into consideration not only statistical results but clinical practice as well, a more realistic reference range of 1.9 - 5.7 pmol/l can be recommended. Additional informationStorage Store the reagents between 2-8 °C. At this temperature each reagent is stable until expiry date. Control serum should be aliquotted and stored deep frozen (-20 °C) for a repeated use. Availability From stock. Shelf life The minimum shelf life of kit reagents is usually 8 weeks from the date of manufacturing. The actual expiry date is given on the package label and in the quality certificate. To make the maximum benefit of long-term stability it is recommended to adjust the date of ordering to new-batch manufacturing calendar issued each year. Components from various lots or from kits of different manufacturers should not be mixed or interchanged. PrecautionRadioactivity This product contains radioactive material. It is the responsibility of the user to ensure that local regulations or code of practice related to the handling of radioactive materials are satisfied. Chemical hazard Components contain sodium azide as an antimicrobial agent. Dispose of waste by flushing with copious amount of water to avoid build-up of explosive metallic azides in copper and lead plumbing. The total azide present in each pack is 113.5 mg. Biohazard Human blood products used in the kit have been obtained from healthy human donors. They were tested individually by using approved methods (EIA, enzyme immunoassay), and were found to be negative, for the presence of both Human Immunodeficiency Virus antibody (Anti-HIV-1) and Hepatitis B surface Antigen (HBsAg). Care should always be taken when handling human specimens to be tested with diagnostic kits. Even if the subject has been tested, no method can offer complete assurance that Hepatitis B Virus, Human Immunodeficiency Virus (HIV-1), or other infectious agents are absent. Human blood samples should therefore be handled as potentially infectious materials.
Products || Technical Support || Search || Sitemap || Contact || Quotation Request |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||